Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is xeroderma pigmentosum a contraindication for adjuvant radiation therapy to the breast in the breast conservation setting?
Answer from: Radiation Oncologist at Community Practice
It’s not a contraindication to RT as DSB caused by ionizing RT is not the same as damage caused by exposure to UV rays.
Sign in or Register to read more
8736
Related Questions
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
Do you consider chest wall constraints when treating with 5-fraction APBI?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
When should the dissected axilla (levels I-II) be included when delivering RNI?
Do you offer APBI to patients who do not have surgical clips but a visible seroma?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
What is your approach to a tumor bed boost in early stage breast cancer patients with micrometastasis?
How would you manage a patient presenting with recurrent cT4 breast cancer?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?